Mater Research - University of Queensland, Translational Research Institute, Australia.
School of Veterinary Science, The University of Queensland, Australia.
Drug Discov Today. 2019 Jan;24(1):37-41. doi: 10.1016/j.drudis.2018.09.001. Epub 2018 Sep 7.
Thiopurine drugs continue to be a cornerstone of inflammatory bowel disease (IBD) treatment. Thiopurines are economical compared with many newer medical treatments for IBD, other chronic inflammatory diseases and leukaemia, although they are not without their shortcomings. These include a slow-onset therapeutic action and many adverse drug reactions. This feature article surveys published data, unpublished in vitro and in vivo experiments, as well as clinical experience, underpinning a rationale for bringing a novel thiopurine drug formulation to market. This formulation has a rapid action making it suitable for the induction and maintenance treatment of IBD and avoids most thiopurine-associated adverse reactions.
硫唑嘌呤类药物仍然是炎症性肠病 (IBD) 治疗的基石。与许多用于治疗 IBD、其他慢性炎症性疾病和白血病的新型药物相比，硫唑嘌呤类药物的价格较为经济实惠，虽然它们也并非没有缺点。这些缺点包括起效缓慢和许多药物不良反应。本文综述了已发表的数据、未发表的体外和体内实验以及临床经验，为将一种新型硫唑嘌呤类药物制剂推向市场提供了理论依据。这种制剂具有快速作用，适用于 IBD 的诱导和维持治疗，可以避免大多数与硫唑嘌呤相关的不良反应。
